


REMARKS

This Preliminary Amendment puts the claims into proper form for examination. Notes that claims 3-5 and 7 have been amended; new claims 10-12 have been added; and claims 1, 2, 6, 8, and 9 remain unchanged. Kindly calculate the filing fee based on the amended claims.

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter which would expedite allowance of the present application.

Respectfully submitted,

WALTER SCHUBERT

By: 
Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant

WEINGARTEN, SCHURGIN, GAGNEBIN
& HAYES LLP
Ten Post Office Square
Boston, MA 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

Date: 3-14-1

CLG/mc/245600-1

Red-lined claims for the Examiner's convenience

3. The process as claimed in ~~one of the preceding claims~~ 1 wherein said surface is a human or animal tissue section and/or endothelioid cells and/or protein chips and/or a cultivated piece of human or animal tissue.

4. The process as claimed in ~~one of the preceding claims~~ 1 wherein the cell-specific target structures are identified in a process comprising the following steps:

- (V) automatically depositing a reagent solution Y1 that includes at least one marker molecule on said cell-specific target structure;
- (VI) allowing the reagent solution Y1 to react, and automatically detecting at least one marker pattern of the target structure labeled with the reagent solution Y1;
- (VII) removing said reagent solution Y1 before or after detecting the marker pattern, and repeating steps (I) and (II) with further reagent solutions Yn (n = 2, 3, ..., N) each containing said at least one marker molecule and/or at least another marker molecule; and

(VIII) combining the marker patterns detected in step (II)
to give a complex molecular combination pattern of
the cell-specific target structure.

5. The process as claimed in ~~one of the preceding claims~~ 1
wherein the selected target structures are biochemically
characterized in procedural step e) by means of a molecule or
molecular complex separation process, in particular a protein
separation process.

7. The process as claimed in ~~one of the preceding claims~~ 1
wherein the following procedural step is performed after
procedural step d):

d1) conducting inhibition experiments regarding one or
plural ingredients of the cell-specific target structures
selected in procedural step (d) for detecting a binding
hierarchy of the ingredients.